Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
Phone+1-614-7937500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees14
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions
What is Navidea Biopharmaceuticals' stock symbol?
Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."
How were Navidea Biopharmaceuticals' earnings last quarter?
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) announced its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17). The biopharmaceutical company earned $0.24 million during the quarter. View Navidea Biopharmaceuticals' Earnings History.
When is Navidea Biopharmaceuticals' next earnings date?
What price target have analysts set for NAVB?
1 Wall Street analysts have issued 12 month price targets for Navidea Biopharmaceuticals' stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Navidea Biopharmaceuticals' stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 153.2% from the stock's current price. View Analyst Price Targets for Navidea Biopharmaceuticals.
What is the consensus analysts' recommendation for Navidea Biopharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Navidea Biopharmaceuticals.
Has Navidea Biopharmaceuticals been receiving favorable news coverage?
Media stories about NAVB stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Navidea Biopharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Navidea Biopharmaceuticals.
Are investors shorting Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,220,000 shares, an increase of 85.7% from the September 30th total of 656,900 shares. Based on an average daily trading volume, of 546,900 shares, the days-to-cover ratio is presently 2.2 days. Currently, 10.5% of the company's shares are sold short. View Navidea Biopharmaceuticals' Current Options Chain.
Who are some of Navidea Biopharmaceuticals' key competitors?
Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).
What other stocks do shareholders of Navidea Biopharmaceuticals own?
Who are Navidea Biopharmaceuticals' key executives?
Navidea Biopharmaceuticals' management team includes the folowing people:
- Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)
- Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer
- Erika Gibson, Director of Fin. & Admin.
- Mr. William J. Regan, Chief Compliance Officer (Age 67)
- Ms. Sharon Correia, Sr. Director of Corp. Communications
How do I buy shares of Navidea Biopharmaceuticals?
Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Navidea Biopharmaceuticals' stock price today?
One share of NAVB stock can currently be purchased for approximately $0.79.
How big of a company is Navidea Biopharmaceuticals?
What is Navidea Biopharmaceuticals' official website?
How can I contact Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.
MarketBeat Community Rating for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
